Rep. Kevin Hern Unloads Shares of Novartis AG (NYSE:NVS)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Novartis stock on August 27th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novartis Stock Down 0.9%

NYSE:NVS traded down $1.32 during trading hours on Tuesday, hitting $145.56. 1,575,287 shares of the stock traded hands, compared to its average volume of 1,998,925. The firm has a 50 day moving average price of $151.62 and a 200 day moving average price of $151.15. The firm has a market cap of $277.75 billion, a price-to-earnings ratio of 21.95, a PEG ratio of 2.81 and a beta of 0.45. Novartis AG has a fifty-two week low of $121.57 and a fifty-two week high of $170.46. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Equities research analysts anticipate that Novartis AG will post 8.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. QRG Capital Management Inc. grew its holdings in shares of Novartis by 9.0% in the 2nd quarter. QRG Capital Management Inc. now owns 164,478 shares of the company’s stock valued at $25,777,000 after buying an additional 13,634 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in shares of Novartis by 3.9% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 19,022 shares of the company’s stock valued at $2,981,000 after purchasing an additional 713 shares during the period. Envestnet Asset Management Inc. lifted its stake in Novartis by 0.8% in the second quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock valued at $365,308,000 after buying an additional 19,595 shares in the last quarter. Silicon Valley Capital Partners increased its position in shares of Novartis by 519.4% during the second quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after acquiring an additional 161 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new stake in Novartis in the 2nd quarter valued at $4,529,000. Institutional investors own 13.12% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on NVS shares. HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and increased their target price for the company from $123.00 to $136.00 in a research note on Thursday, September 10th. Royal Bank Of Canada initiated coverage on shares of Novartis in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Thursday, September 17th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Finally, Citigroup reissued a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Six analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $148.40.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.